0.0850EUR-4.49%Mkt Cap: 20.00M EURP/E: —Last update: 2026-05-14
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company deve…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-0.17
PEG—
P/B-0.75
P/S30.68
EV/EBITDA-2.66
EV/Revenue44.85
EPS (TTM)-0.08
EPS (Forward)-0.50
Cash Flow & Leverage
FCF Yield-36.21%
FCF Margin-1110.64%
Operating CF-9.17M EUR
CapEx (TTM)4.00K EUR
Net Debt/EBITDA-0.95
Net Debt10.45M EUR
Technical
SMA 500.0858 (-0.9%)
SMA 2000.1107 (-23.2%)
Beta0.61
S&P 52W Chg24.23%
Avg Vol (30d)602.11K
Avg Vol (10d)1.17M
Technical Indicators
RSI (14)52.3
MACD0.0001
MACD Signal-0.0006
MACD Hist.+0.0007
BB Upper0.0873 EUR
BB Middle0.0826 EUR
BB Lower0.0780 EUR
BB Width11.19%
ATR (14)0.0038 EUR
Vol Ratio (20d)0.86x
52W Range
0.07525% of range0.2700
52W High0.2700 EUR
52W Low0.0752 EUR
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin-1203600.00%
Oper. Margin-705.96%
ROE48.26%
ROA-145.78%
Revenue Growth-32.70%
Earnings Growth—
Balance Sheet
Debt/Equity-0.52
Current Ratio0.39
Quick Ratio0.32
Book Value/Sh-0.1130 EUR
Cash/Share0.0110 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.234.47M
Float149.93M
Insiders7.07%
Institutions46.31%
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)0.3050 EUR
Target Range0.2100 EUR – 0.4000 EUR
# Analysts2
Company
Market Cap20.00M EUR
Enterprise Value29.24M EUR
Revenue (TTM)652.00K EUR
Gross Profit652.00K EUR
Net Income (TTM)-12.04M EUR
Revenue/Share0.0040 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees13
Last Price0.0850 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013183985